Close

Press Releases

WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

WuXi Biologics , a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its...

Clinerion and Datametrix partner to deliver RWE insights from Real World Data from Clinerion’s global hospital network

The partners will deliver an integrated clinical research offer transforming Real World Data (RWD) from the global site and patient network on Clinerion’s Patient Network Explorer into Real World Evidence (RWE) through the use of Datametrix’s analytical capabilities. Together, Clinerion...

Ministry of MSME, GoI partners with Telangana Government for BioAsia 2020 to add impetus to the Life Sciences MSMEs

The Micro, Small and Medium Enterprises (MSME) sector has emerged as a dynamic sector of the Indian economy over a few years. It contributes significantly to the economic and social development of the country by encouraging entrepreneurship and generating...

Eisai’s DAYVIGO gets approval in Japan to treat insomnia

Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia. DAYVIGO is a dual orexin receptor antagonist...

First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure

Imagine a world where those living with Type 1 Diabetes, a chronic illness affecting more than 60 million adults globally, no longer had to deal with regular blood glucose monitoring, daily insulin injections or life-threatening nighttime hypoglycemic events, but...

Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc

Eisai Co., Ltd. announced that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research. In this joint research and development, Eisai and...

Medigene, IRICoR and Universite de Montreal sign collaboration and exclusive licensing option on novel cancer antigens

Medigene AG , a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that it has entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with the Universite de Montreal (UdeM) and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read